To determine whether BRD4 can be a therapeutic target in liver cancer, we first examined the expression of BRD4 in three large publically available cohorts of human HCC patients from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) data base (GSE25097, GSE36376 and GSE45436), since intuitively overexpressed expression is more likely (but not always) functionally relevant. This evidence concerns the gene BRD4 and liver cancer.